# OMAHA-004 (NCT06136650)

> A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

No report yet. It can be ordered.

- Drugs tested: opevesostat
- Indication: metastatic castration-resistant prostate cancer post one NHA

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06136650
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
- Interventions: Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide
- Enrollment: 1314
- Primary outcome: Overall Survival (OS)

## Indexed commentary on OMAHA-004 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- YouTube: 1
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=omaha-004-nct06136650

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06136650", "email": "<work email>"}; the inbox owner confirms by the emailed link.